<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895101</url>
  </required_header>
  <id_info>
    <org_study_id>TA-1251</org_study_id>
    <secondary_id>2013-000774-30</secondary_id>
    <nct_id>NCT01895101</nct_id>
  </id_info>
  <brief_title>The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients</brief_title>
  <official_title>The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphia Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It remains still unclear whether topical tranexamic acid has an added value besides the
      administration of intravenously tranexamic acid. We hypothesize that the addition of topical
      tranexamic acid, besides intravenous administration of tranexamic acid, results in a 25%
      reduction of post-operative blood loss after cardiac surgery.

      The aim of this study is to determine whether the application of topical tranexamic acid
      reduces the 12 hours postoperative blood loss by 25% in patient scheduled for cardiac surgery
      on cardiopulmonary bypass, whereby intravenous tranexamic acid is administrated.

      Just before sternal closure, 250 subjects receives pericardial lavage with 2 gr tranexamic
      acid in 200 ml normothermic saline solution (NaCl 0.9%), 250 subjects receives pericardial
      lavage with 200 ml normothermic saline solution without TA and 250 subjects (control group)
      receives no pericardial lavage. The main study parameter is 12 hours post-operative blood
      loss and is assessed by 12 hours post-operative chest tube production.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Blood Loss</measure>
    <time_frame>12 hours postoperative</time_frame>
    <description>The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Surgical Re-exploration</measure>
    <time_frame>participants will be followed for the duration of ICU stay, an expected average of 2 days</time_frame>
    <description>the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Red Blood Cell Transfusions (Cumulative of Pre, Peri and Postoperative Period)</measure>
    <time_frame>participants will be followed for the duration of ICU stay, an expected average of 2 days/ And participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Blood Loss</condition>
  <condition>Tranexamic Acid</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>pericardial lavage with 200 ml normothermic saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No pericardial lavage</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 gr tranexamic acid diluted in 200 ml normothermic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 gr tranexamic acid</intervention_name>
    <description>This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
    <arm_group_label>2 gr tranexamic acid diluted in 200 ml normothermic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
    <arm_group_label>pericardial lavage with 200 ml normothermic saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender; male/ female

          -  Age: â‰¥ 18 year

          -  Elective cardiac surgical patients

               -  Coronary artery bypass graft (CABG) (conventional, E.CCO)

               -  Aortic valve replacement (AVR) (conventional)

               -  Mitral valve replacement (MVR)/ Mitral valve repairment (MPL) (conventional)

               -  Tricuspid valve replacement (TVR) / Tricuspid valve repairment (TPL)

               -  Bentall

               -  Combined procedure (e.g. CABG/ AVR, MVR/AVR, AVR/Maze)

        Exclusion Criteria:

          -  MVR/MPL (minimal invasive, Port Access Surgery)

          -  Maze (minimal invasive, via Thoracoscopy)

          -  AVR (minimal invasive, via mini Sternotomy)

          -  off-pump procedures

          -  Emergency operations

          -  Patient with increased or decreased blooding tendency (FV leiden, prot C, S
             deficiency, anti-thrombin deficiency, prothrombin mutation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Scohy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amphia Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <zip>4800 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Mahaffey R, Wang L, Hamilton A, Phelan R, Arellano R. A retrospective analysis of blood loss with combined topical and intravenous tranexamic acid after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2013 Feb;27(1):18-22. doi: 10.1053/j.jvca.2012.08.004. Epub 2012 Oct 10.</citation>
    <PMID>23063104</PMID>
  </reference>
  <reference>
    <citation>De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80.</citation>
    <PMID>10694619</PMID>
  </reference>
  <reference>
    <citation>Baric D, Biocina B, Unic D, Sutlic Z, Rudez I, Vrca VB, Brkic K, Ivkovic M. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg. 2007 Mar;31(3):366-71; discussion 371. Epub 2007 Jan 10.</citation>
    <PMID>17218108</PMID>
  </reference>
  <reference>
    <citation>Abul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol. 2006 May;23(5):380-4. Epub 2006 Jan 27.</citation>
    <PMID>16438759</PMID>
  </reference>
  <reference>
    <citation>Spegar J, Vanek T, Snircova J, Fajt R, Straka Z, Pazderkova P, Maly M. Local and systemic application of tranexamic acid in heart valve surgery: a prospective, randomized, double blind LOST study. J Thromb Thrombolysis. 2011 Oct;32(3):303-10. doi: 10.1007/s11239-011-0608-3.</citation>
    <PMID>21660523</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>March 30, 2015</results_first_submitted>
  <results_first_submitted_qc>March 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2015</results_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Amphia Hospital</investigator_affiliation>
    <investigator_full_name>Thierry V Scohy</investigator_full_name>
    <investigator_title>MD, phd</investigator_title>
  </responsible_party>
  <keyword>blood loss</keyword>
  <keyword>tranexamix acid</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
        </group>
        <group group_id="P2">
          <title>No Pericardial Lavage</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
        </group>
        <group group_id="P3">
          <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>OPCAB procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>another study, enrolled in other study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>coagulation disorder</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
        </group>
        <group group_id="B2">
          <title>No Pericardial Lavage</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
        </group>
        <group group_id="B3">
          <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="245"/>
            <count group_id="B4" value="739"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="62" upper_limit="75"/>
                    <measurement group_id="B2" value="68" lower_limit="63" upper_limit="76"/>
                    <measurement group_id="B3" value="69" lower_limit="62" upper_limit="75"/>
                    <measurement group_id="B4" value="69" lower_limit="62" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Blood Loss</title>
        <description>The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure</description>
        <time_frame>12 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
          </group>
          <group group_id="O2">
            <title>No Pericardial Lavage</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
          </group>
          <group group_id="O3">
            <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Blood Loss</title>
          <description>The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure</description>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290" lower_limit="210" upper_limit="410"/>
                    <measurement group_id="O2" value="300" lower_limit="190" upper_limit="450"/>
                    <measurement group_id="O3" value="290" lower_limit="190" upper_limit="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Surgical Re-exploration</title>
        <description>the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol.</description>
        <time_frame>participants will be followed for the duration of ICU stay, an expected average of 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
          </group>
          <group group_id="O2">
            <title>No Pericardial Lavage</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
          </group>
          <group group_id="O3">
            <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Surgical Re-exploration</title>
          <description>the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Red Blood Cell Transfusions (Cumulative of Pre, Peri and Postoperative Period)</title>
        <description>The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital.</description>
        <time_frame>participants will be followed for the duration of ICU stay, an expected average of 2 days/ And participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
          </group>
          <group group_id="O2">
            <title>No Pericardial Lavage</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
          </group>
          <group group_id="O3">
            <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
            <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Red Blood Cell Transfusions (Cumulative of Pre, Peri and Postoperative Period)</title>
          <description>The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital.</description>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.6"/>
                    <measurement group_id="O2" value="1.1" spread="3.2"/>
                    <measurement group_id="O3" value="0.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pericardial Lavage With 200 ml Normothermic Saline Solution</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid.
Saline: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid</description>
        </group>
        <group group_id="E2">
          <title>No Pericardial Lavage</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
In this arm the subjects receives as in standard care no pericardial lavage.</description>
        </group>
        <group group_id="E3">
          <title>2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline</title>
          <description>According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%).
2 gr tranexamic acid: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>epileptic seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thierry V Scohy</name_or_title>
      <organization>Amphia Hospital</organization>
      <phone>0031765955570</phone>
      <email>tscohy@amphia.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

